XXXX Thanks, update. Jayne, to us today review Infinity's and to business second quarter joining thanks everyone for
for benefit as discussed treatment, last derived in solid thereby our May, clinical for this better to and therapies. of potential partnerships at this. generation to on to evaluation Infinity who eganelisib are we little eganelisib from enable especially the we need to goal, patients of first pursuing who goal tumors maximize additional and value achieve shareholders, are long we immuno-oncology those been have To the on bring Our has most focused to no patients its expanding call recent
partnering. We have objectives in two
the solid belief across expand the to eganelisib partners with potentially regimens. a of and of to eganelisib R&D our the magnitude drugs shares opportunity extensive to partner eganelisib an of program, broad willing a is array and prospective create differentiated combining fund development with First, tumors who treatment
to establish to of our the structure Since our potential that put value last shareholders. of have prior discussions the partnership we for eganelisib, that we given Second, seen in quarterly is completed multiple with with made have we call, place of the a activity in initiating key strategic couple clinical that new midyear we've creation enables a Infinity reasons. our And partnership meaningful a we are options. One we've multiple trials decision partners. review. development And for breadth
that our on constructive. can studies, decisions input partners prospective combination with accommodate strategy very development collaborating is on such, of so new prioritization on their As drug we including clinical to eganelisib use partners and which design
Two, is activity eganelisib see randomized controlled profile these the Prior the us macrophages a translational therapeutic key progression-free a standards pleased overall after first-in-class and and distinct care resources including importantly, MARIO-XXX. positive our the to regimen. today, In in studies, market us year-end data the ongoing to we safety of current with are prolonged in has report are XXXX three that to and analysis addition, show XXXX. runway has and combination and MARIO-X data clinical showing Clinical immune whose reprograms combination translational response. platinum-based to MARIO-X, Three, three on with survival have tumors eganelisib an in a and that manageable cash urothelial extend allowed over attributes, increase cash starting multiple other to very of it been from regimen. survival drug patients we reasons. indications, eganelisib studies Reflective these immune shown in focusing of given updated importantly results we two survival notable dynamics, with and current drug reduces drugs, cancer, and target eganelisib activates with and have presented guidance our have for trials; One, an demonstrated eganelisib contribution MARIO-XXX acceptable including tumor and over a from clinical its operational two-year with have in treatment microenvironment, allows into in that extended progressed unique our partners. therapy overall immuno-oncology our anti-cancer data new we combination chemotherapy suppression trial candidate on
to in detail. trend survival of of end continue this review which and our standard will of of lines the trial of for with PD-LX arm need unmet be see in now in the no over safety will great Rob period outcomes to will We're care Rob low durable year review. areas signals of in by both the treatment, updated frontline, patients evidence encouraged increasingly since benefit this that during of the with meaningfully very and indications, new breast We our more extended By study, negative control Rob? from across triple in data a review October cancer combinations, therapy mature MARIO-X improved year, a high which PFS of data we encouraging of also wide show last XXXX. will PD-X which and a continue tumors, full patients range data cut consistent
